Quantitation of 2-hydroxyglutarate in human plasma via LC–MS/MS using a surrogate analyte approach

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Geisbrecht B, Gould S. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem. 274(43), 30527–30533 (1999).
  Medline CASGoogle Scholar
• 2. Wang F, Travins J, De La Barre B et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340(6132), 622–626 (2013).
  Medline CASGoogle Scholar
• 3. Hamamoto T, Munakata R, Tajiri R et al. Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies. J. Histochem. Cytochem. 49(9), 1123–1131 (2001).
  MedlineGoogle Scholar
• 4. Saha SK, Parachoniak CA, Ghanta KS et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513(7516), 110–114 (2014).
  Medline CASGoogle Scholar
• 5. Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390), 474–478 (2012).
  Medline CASGoogle Scholar
• 6. Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1), 17–30 (2011).
  Medline CASGoogle Scholar
• 7. Hollenbach PW, Nguyen AN, Brady H et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5(2), e9001 (2010).
  MedlineGoogle Scholar
• 8. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274), 739–744 (2009).
  Medline CASGoogle Scholar
• 9. Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207(2), 339–344 (2010).
  Medline CASGoogle Scholar
• 10. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3), 225–234 (2010).
  Medline CASGoogle Scholar
• 11. Fathi AT, Sadrzadeh H, Borger DR et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120(23), 4649–4652 (2012).
  Medline CASGoogle Scholar
• 12. Popovici-Muller J, Lemieux RM, Artin E et al. Discovery of AG-120 (Ivosidenib): a first in class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med. Chem. Lett. 9(4), 300–305 (2018).
  Medline CASGoogle Scholar
• 13. McGehee E, Rakheja D, Oliver D et al. The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia. Br. J. Haematol. 173(2), 314–328 (2016). • A reference to report (D)-2-HG is the major oncometabolite from IDH mutations.
  MedlineGoogle Scholar
• 14. Fan B, Mellinghoff I, Wen P et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest. New Drug 38(2), 433–444 (2020).
  Medline CASGoogle Scholar
• 15. Delahousse J, Verlingue L, Broutin S et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase mutated intrahepatic cholangiocarcinomas. Eur. J. Cancer 90, 83–91 (2018).
  Medline CASGoogle Scholar
• 16. US FDA. Biomarker Qualification: Evidentiary Framework (2018). https://www.fda.gov/media/122319/download
  Google Scholar
• 17. Jones BR, Schultz GA, Eckstein JA et al. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis 4(19), 2343–2356 (2012). • An overview of biomarker quantitation using surrogate matrix or surrogate analyte approaches.
  CASGoogle Scholar
• 18. Chen J, Tabatabaei A, Zook D et al. A surrogate analyte-based liquid chromatography–tandem mass spectrometry method for the determination of endogenous cyclic nucleotides in rat brain. J. Pharm. Biomed. Anal. 146, 361–368 (2017).
  Medline CASGoogle Scholar
• 19. Sidhu R, Jiang H, Farhat NY et al. A validated LC–MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J. Lipid Res. 56(6), 1222–1233 (2015).
  Medline CASGoogle Scholar
• 20. Yin F, Keller J, Kraus D et al. A double surrogate approach for the quantitation of 2-hydroxyglutarate – an oncometabolite in human brain tumors via LC–MS/MS. J. Pharm. Biomed. Anal. 179, 112916 (2020). • The first paper to report a bioanalytical method using surrogate analyte in surrogate matrix approach.
  Medline CASGoogle Scholar
• 21. US FDA. Bioanalytical Method Validation Guidance for Industry (2018). https://www.fda.gov/media/70858/download •• New guidance from US FDA for bioanalytical method validation.
  Google Scholar